Evidence map›Paper›PMID 42092174›Full record

ArticleProstate cancer and prostatic diseases2026

Predictors of durability of the prostatic urethral lift (PUL) for benign prostatic hyperplasia.

Gregg Eure, Matt Ashley, Daniel B Rukstalis, Peter Chin, Neil Barber, Claus Roehrborn

Abstract read
In one paragraph

Article in Prostate cancer and prostatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gregg EureUrology of Virginia, Culpeper, VA, USA. greggeure@urologyofva.net.ORCID http://orcid.org/0000-0002-1110-5591
Matt AshleySummit Health, Bend, OR, USA.
Daniel B RukstalisCarilion Clinic, Roanoke, VA, USA.
Peter ChinSouth Coast Urology, Wollongong, NSW, Australia.
Neil BarberFrimley Park Hospital, Frimley, UK.
Claus RoehrbornUT Southwestern, Dallas, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is a need to understand the predictors of prostatic urethral lift (PUL) durability to help physicians counsel patients and optimize outcomes.

methodsA simple logistic regression analysis was performed on a pooled dataset of 331 subjects across 5 PUL controlled studies with up to 5 years follow up. Predictors of "surgical durability" (no surgical treatment for return of symptoms) and "total durability" (no surgical or medical treatment for return of symptoms) were assessed at 1- and 5-year post-procedure.

resultsPlacing ≤4 implants regardless of baseline prostate volume was associated with increased surgical retreatment within the first year. Through one year, more implants were protective of retreatment; for every incremental implant placed, surgical retreatment odds decreased an additional 41.2% and risk of combined surgical or medical retreatment decreased 30.2%. Higher implant density was also protective through one year; for each additional implant placed per 10cc prostate volume, surgical retreatment odds decreased incrementally by 79.0%. Up to 5 years, a higher baseline pretreatment IPSS score predicted higher rates of surgical or medical retreatment; for every one-point score increase of baseline IPSS, surgical or medical retreatment odds increased 5.2%. Baseline demographics, medical history and baseline sexual function were not predictors of surgical or total durability.

conclusionsMore implants, higher implant density, and lower baseline IPSS are all associated with decreased surgical and medical retreatment rates up to 5 years following PUL. These findings inform optimizing PUL technique, considering earlier intervention and counseling men on outcomes prior to PUL.

Indexed as

ProstateProstatic HyperplasiaUrethraAgedFollow-Up StudiesHumansMaleMiddle AgedProstheses and ImplantsTreatment Outcome

Identifiers

PMID42092174
PMCPMC13623641

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.